Effects of Chlordiazepoxide and Imipramine on Maze Patrolling Within Two Different Maze Configurations by Psychogenetically Selected Lines of Rats
Overview
Authors
Affiliations
Male rats of two lines of rats psychogenetically selected and bred for extremes in performance in shuttle box avoidance received an acute IP injection of chlordiazepoxide (CDP; 2.5, 5.0, 10.0 mg/kg), imipramine HCl (IMI: 0.33, 1.0, or 3.0 mg/kg), or vehicle. The rats were placed, 35 min after injection, in an enclosed maze with either a simple configuration with an unilluminated central arena or a complex configuration with a brightly illuminated central arena, and spontaneous maze patrolling was evaluated. Total locomotor activity during the 6-min maze test was significantly reduced by 5--10 mg/kg CDP for both RHA/Verh and RLA/Verh lines of rats in both the simple and the complex maze configurations. Treatment with 10 mg/kg CDP reduced the total explored area for both rat lines in both maze configurations. In addition, the maze area explored by RHA/Verh rats was also reduced by 5.0 mg/kg CDP for the simple configuration and by 2.5 and 5.0 mg/kg CDP for the complex configuration. Entry into the unilluminated central field of the simple maze was reduced by 5--10 mg/kg CDP only in RHA/Verh rats. In contrast, 2.5 mg/kg CDP significantly increased entry into the brightly illuminated central arena of the complex maze for the RLA/Verh rats. The doses of IMI used were without effect on the parameters of maze patrolling behavior evaluated, with the single exception that the locomotor activity of RHA/Verh rats tested in the simple maze configuration was decreased by 3.0 mg/kg IMI. The results indicate that, although the effects of CDP were generally similar for total activity and the area explored in the two psychogenetic lines investigated, there was a qualitative difference in its effect on entry into an illuminated arena.
Giorgi O, Corda M, Fernandez-Teruel A Front Behav Neurosci. 2019; 13:145.
PMID: 31333426 PMC: 6624787. DOI: 10.3389/fnbeh.2019.00145.
Dion A, Sanderson S, Murrin L, Bevins R Pharmacol Biochem Behav. 2011; 100(3):419-24.
PMID: 22005597 PMC: 3242910. DOI: 10.1016/j.pbb.2011.10.003.
Driscoll P, Ferre P, Fernandez-Teruel A, Levi de Stein M, Wolfman C, Medina J Psychopharmacology (Berl). 1995; 122(1):51-7.
PMID: 8711064 DOI: 10.1007/BF02246441.
Fernandez-Teruel A, Escorihuela R, Driscoll P, Tobena A, BATTIG K Behav Genet. 1994; 24(5):419-25.
PMID: 7993318 DOI: 10.1007/BF01076177.
Br J Pharmacol. 1984; 83 Suppl:349P-463P.
PMID: 6509265 PMC: 1986970.